Squawk on the Street cover image

Trump's Tariff Threat, Retail Earnings Ahead of Black Friday, Amgen Tumbles on Weight-Loss Drug Data 11/26/24

Squawk on the Street

CHAPTER

Amgen's Weight Loss Drug Woes

This chapter examines Amgen's declining stock performance linked to concerns over its experimental weight loss drug and its mixed results in trials. It also discusses the broader market implications of the Biden administration's efforts to expand access to obesity treatments and the volatility in futures trading.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner